<DOC>
	<DOC>NCT01031836</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and tolerability of MEDI-545 in Japanese adult SLE patients. This will be done by collecting the data from 3 cohorts of IV doses and 1 cohort of SC doses.</brief_summary>
	<brief_title>A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients must have previously met ≥4 of the 11 revised ACR criteria Have positive antinuclear antibody test (ANA) at ≥1:80 serum dilute in the past or at screening Have at least 1 system with a score of A or 2 systems with a score of B on the BILAG index at screening, or have a SELENASLEDAI score ≥6 Have received prednisone &gt;20 mg/day (or an equivalent dose of another oral corticosteroid) within 14 days before Visit 2 (Day 1) Have received the following medications within 28 days before Visit 2 (Day 1): Systemic cyclophosphamide at any dose Cyclosporine at any dose Tacrolimus at any dose Thalidomide at any dose Mycophenolate mofetil &gt;2 g/day Methotrexate &gt;15 mg/week Azathioprine &gt;2 mg/kg/day Women who have a positive pregnancy test (serum hCG) at Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Japanese</keyword>
	<keyword>phase 2</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>MEDI-545</keyword>
	<keyword>Autoimmune Disease</keyword>
	<keyword>Immune System Diseases</keyword>
</DOC>